Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
« Previous Article | Table of Contents | Next Article »
Arteriosclerosis, Thrombosis, and Vascular Biology. 1986;6:203-211

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by DiMinno, G.
Right arrow Articles by Mancini, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by DiMinno, G.
Right arrow Articles by Mancini, M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*ACETYLSALICYLIC ACID
*Genetics Home Reference

Arteriosclerosis, Vol 6, 203-211, Copyright © 1986 by American Heart Association

ARTICLES

Increased fibrinogen binding to platelets from patients with familial hypercholesterolemia

G DiMinno, MJ Silver, AM Cerbone, A Rainone, A Postiglione and M Mancini

Familial hypercholesterolemia (FH) is a disease marked by a high incidence of thrombotic episodes and hypersensitivity of the patients' platelets to naturally occurring aggregating agents. Prostaglandin/thromboxane (PG/Tx) formation, adenosine 5'-diphosphate (ADP) secretion, and fibrinogen binding to platelets are all believed to be involved in the mechanisms of platelet aggregation. Therefore, we studied the interrelated roles of these processes in the platelets of nine FH patients and 10 controls. In response to ADP, collagen, or thrombin, FH platelets bound about twice as much 125I-fibrinogen as controls. This ratio did not change after suppression of PG/Tx formation by aspirin. With or without aspirin, FH platelets always aggregated in response to significantly lower concentrations of these agents than did platelets from normal controls. After stimulation with thrombin or collagen, the hyperaggregable platelets from FH patients were shown to bind significantly more fibrinogen than control platelets even when PG/Tx formation was suppressed (aspirin) and secreted ADP was scavenged (apyrase). To determine whether the increased fibrinogen binding observed in FH platelets is due to a qualitative or quantitative abnormality of the platelet receptor, we used a monoclonal antibody (B79.7) that is specific for the receptor. The amount of B79.7 that bound to platelets from control and FH subjects was similar. In addition (as in normal individuals), the antibody inhibited aggregation and fibrinogen binding of FH platelets.


This article has been cited by other articles:


Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
D. T. Eitzman, R. J. Westrick, Z. Xu, J. Tyson, and D. Ginsburg
Hyperlipidemia Promotes Thrombosis After Injury to Atherosclerotic Vessels in Apolipoprotein E-Deficient Mice
Arterioscler Thromb Vasc Biol, July 1, 2000; 20(7): 1831 - 1834.
[Abstract] [Full Text] [PDF]

Home page
 J CARDIOVASC PHARMACOL THERHome page
A. Corsini
Reviews: Fluvastatin: Effects Beyond Cholesterol Lowering
Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2000; 5(3): 161 - 175.
[Abstract] [PDF]

Home page
 CirculationHome page
A. M. Carter, N. Ossei-Gerning, I. J. Wilson, and P. J. Grant
Association of the Platelet PlA Polymorphism of Glycoprotein IIb/IIIa and the Fibrinogen Bß 448 Polymorphism With Myocardial Infarction and Extent of Coronary Artery Disease
Circulation, September 2, 1997; 96(5): 1424 - 1431.
[Abstract] [Full Text]

Home page
 CirculationHome page
L. Lacoste, J. Y.T. Lam, J. Hung, G. Letchacovski, C. B. Solymoss, and D. Waters
Hyperlipidemia and Coronary Disease : Correction of the Increased Thrombogenic Potential With Cholesterol Reduction
Circulation, December 1, 1995; 92(11): 3172 - 3177.
[Abstract] [Full Text]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
A. Notarbartolo, G. Davi, M. Averna, C. M. Barbagallo, A. Ganci, C. Giammarresi, F. P. L. Placa, and C. Patrono
Inhibition of Thromboxane Biosynthesis and Platelet Function by Simvastatin in Type IIa Hypercholesterolemia
Arterioscler Thromb Vasc Biol, February 1, 1995; 15(2): 247 - 251.
[Abstract] [Full Text]

Home page
 ANGIOLOGYHome page
E. Ernst
Fibrinogen: Its Emerging Role as a Cardiovascular Risk Factor
Angiology, February 1, 1994; 45(2): 87 - 93.
[Abstract] [PDF]


ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 1986 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.